84 Result(s)
within
Jonas Bergh
English
-
Article
Open AccessFive-year follow-up of the OptiTrain trial on concurrent resistance and high-intensity interval training during chemotherapy for patients with breast cancer
The protocol predefined aim of this study is to assess sustained effects of the OptiTrain trial on several health outcomes, 5 years after the baseline assessment. The OptiTrain study was a prospective, randomi...
-
Article
Open AccessA population-based study on trajectories of HER2 status during neoadjuvant chemotherapy for early breast cancer and metastatic progression
This study aimed to investigate the distribution and changes of HER2 status in untreated tumours, in residual disease and in metastasis, and their long-term prognostic implications.
-
Article
Open AccessLongitudinal molecular profiling elucidates immunometabolism dynamics in breast cancer
Although metabolic reprogramming within tumor cells and tumor microenvironment (TME) is well described in breast cancer, little is known about how the interplay of immune state and cancer metabolism evolves du...
-
Article
Open AccessCurrent status of contemporary diagnostic radiotracers in the management of breast cancer: first steps toward theranostic applications
Expanding therapeutic possibilities have improved disease-related prospects for breast cancer patients. Pathological analysis on a tumor biopsy is the current reference standard biomarker used to select for tr...
-
Article
Open AccessAdherence to endocrine therapy in early breast cancer in relation to Cytochrome P450 2D6 genotype: a comparison between pharmacy dispensation data and medical records
Suboptimal adherence to adjuvant endocrine treatment (AET) is an important clinical concern. A correlation between CYP2D6 activity and tamoxifen discontinuation has been described. The main aim of this study w...
-
Article
Open AccessWomen with short survival after diagnosis of metastatic breast cancer: a population-based registry study
Despite therapeutic advances, overall survival of metastatic breast cancer (MBC) at the population level has seen little improvement over the past decades. Aggressive tumor biology or delay in access to cancer...
-
Article
Open AccessAuthor Correction: The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology
-
Article
The value of anticancer drugs — a regulatory view
The high prices of new anticancer drugs and the marginal added benefit perceived by some stakeholders have fuelled a debate on the value of anticancer drugs in the European Union, even though an agreed definit...
-
Article
Open AccessThe Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology
There is a growing need for systems that efficiently support the work of medical teams at the precision-oncology point of care. Here, we present the implementation of the Molecular Tumor Board Portal (MTBP), a...
-
Article
Open AccessImpact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients
Change in mammographic density has been suggested to be a proxy of tamoxifen response. We investigated the effect of additional adjuvant systemic therapy and CYP2D6 activity on MD change in a cohort of tamoxif...
-
Article
Open AccessInterplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study
Emerging data indicate that genomic alterations can shape immune cell composition in early breast cancer. However, there is a need for complementary imaging and sequencing methods for the quantitative assessme...
-
Article
A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy
Endocrine therapy (ET) is an effective strategy to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer (ABC) but nearly all patients eventually...
-
Article
Open AccessEvidence-based prediction and prevention of cardiovascular morbidity in adults treated for cancer
Cancer treatment-related morbidity relevantly compromises health status in cancer survivors, and efforts to optimise health-related outcomes in this population are vital to maximising healthy survivorship. A p...
-
Article
Open AccessA phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
Xentuzumab—a humanised IgG1 monoclonal antibody—binds IGF-1 and IGF-2, inhibiting their growth-promoting signalling and suppressing AKT activation by everolimus. This phase Ib/II exploratory trial evaluated xe...
-
Article
A pan-cancer analysis of the frequency of DNA alterations across cell cycle activity levels
Pan-cancer genomic analyses based on the magnitude of pathway activity are currently lacking. Focusing on the cell cycle, we examined the DNA mutations and chromosome arm-level aneuploidy within tumours with l...
-
Article
Author Correction: Caring for patients with cancer in the COVID-19 era
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
-
Article
Open AccessChemotherapy use near the end-of-life in patients with metastatic breast cancer
Very few data are available regarding the use of chemotherapy in patients with metastatic breast cancer (MBC) near the end-of-life, i.e., the final month. The aim of this study was to provide a descriptive ana...
-
Article
Open AccessLong-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer
To prospectively compare HRQoL effects of two modern adjuvant chemotherapy breast cancer treatment regimens at six time-points up to 16 months after random assignment.
-
Article
Caring for patients with cancer in the COVID-19 era
The current COVID-19 pandemic challenges oncologists to profoundly re-organize oncological care in order to dramatically reduce hospital visits and admissions and therapy-induced immune-related complications w...
-
Article
Open AccessCETSA-based target engagement of taxanes as biomarkers for efficacy and resistance
The use of taxanes has for decades been crucial for treatment of several cancers. A major limitation of these therapies is inherent or acquired drug resistance. A key to improved outcome of taxane-based therap...
